- Drug Pipelines
- August 2018
- 610 Pages
Global
From €20901EUR$22,000USD£17,979GBP
- Report
- August 2022
- 96 Pages
Global
From €3500EUR$3,946USD£3,116GBP
- Report
- February 2024
- 91 Pages
Global
From €3500EUR$3,946USD£3,116GBP
- Report
- May 2022
- 38 Pages
Global
From €1900EUR$2,000USD£1,634GBP
- Drug Pipelines
- March 2021
Global
From €2375EUR$2,500USD£2,043GBP
- Report
- April 2023
- 160 Pages
Global
From €5699EUR$5,999USD£4,903GBP
The Rheumatoid Arthritis Drug market is a subset of the Immune Disorders Drugs market. It is composed of drugs used to treat rheumatoid arthritis, an autoimmune disorder that causes inflammation of the joints. These drugs are used to reduce inflammation, pain, and stiffness, as well as to prevent joint damage. They can be divided into two categories: disease-modifying antirheumatic drugs (DMARDs) and biologic response modifiers (BRMs). DMARDs are used to slow the progression of the disease, while BRMs are used to reduce inflammation and pain.
The Rheumatoid Arthritis Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less Read more